Estée Lauder Companies
EL
$87.19
-1.31%
Estée Lauder Companies is a global leader in the prestige beauty market, operating across skin care, makeup, fragrance, and hair care with iconic brands such as Estée Lauder, Clinique, M.A.C, and La Mer. The company holds a dominant position in the premium segment, with a diversified geographic footprint spanning the Americas, EMEA, and Asia-Pacific, and a strong presence in travel retail. Currently, the stock is in the spotlight following the termination of merger talks with Puig, which investors welcomed as a catalyst for its independent turnaround strategy, while the company continues to navigate a challenging demand environment, particularly in Asia, and works to restore profitability after a period of margin pressure and inventory destocking.…
EL
Estée Lauder Companies
$87.19
Related headlines
Investment Opinion: Should I buy EL Today?
Rating: Hold. The stock is a turnaround play with a consensus 'Buy' rating and an average target price of $95.85, implying ~12% upside. However, the negative trailing EPS and high leverage warrant caution. The thesis is that the company's return to revenue growth and strong gross margins will eventually translate into operating leverage, but the timing is uncertain.
Sign up to view all
EL 12-Month Price Forecast
The AI assessment is neutral with medium confidence. The company shows signs of a turnaround with positive revenue growth and high gross margins, but the operating margin compression and high leverage create uncertainty. The valuation already prices in a strong recovery, leaving little room for error. If the company can demonstrate margin expansion in the next two quarters, the stance would upgrade to bullish. Conversely, if revenue growth decelerates or margins deteriorate further, the stance would turn bearish. The wide analyst target range reflects the high uncertainty in the outlook.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Estée Lauder Companies's 12-month outlook, with a consensus price target around $95.85 and implied upside of +9.9% versus the current price.
Average Target
$95.85
0 analysts
Implied Upside
+9.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$70 - $125
Analyst target range
The target price range spans from a low of $70.00 to a high of $125.00, with the high target implying a 46.2% upside, likely assuming a successful turnaround with margin expansion and revenue growth acceleration. The low target of $70.00 suggests a downside of -18.1%, reflecting risks such as continued weakness in China, competitive pressures, or failure to execute the restructuring plan. The wide spread of $55 between the low and high targets indicates high uncertainty about the company's future performance. Recent institutional ratings have been stable, with no major upgrades or downgrades in the past three months, suggesting analysts are waiting for more evidence of a sustainable recovery before adjusting their outlooks.
Bulls vs Bears: EL Investment Factors
The bull case rests on a return to revenue growth, strong gross margins, and a clear independent turnaround strategy following the termination of merger talks with Puig. The bear case is anchored in persistent share price weakness, negative earnings, high leverage, and a valuation that already prices in a robust recovery. Currently, the bearish evidence is stronger given the stock's technical downtrend and the uncertainty around margin recovery. The most critical tension is whether the company can translate its revenue growth into meaningful operating margin expansion and EPS recovery, as the forward PE of 26.78x leaves little room for error. If margins recover faster than expected, the stock could re-rate higher; if not, it risks falling toward the low analyst target of $70.
Bullish
- Return to Revenue Growth: Q3 FY2026 revenue grew 4.56% YoY to $3.712B, reversing a streak of declines. This marks the first quarter of positive growth after four quarters of stagnation or contraction, signaling a potential inflection in demand.
- High Gross Margin Resilience: Gross margin remained robust at 71.04% in Q3 FY2026, down slightly from 74.96% a year ago but still high for the industry. This provides a strong foundation for operating leverage as sales recover.
- Fragrance and Makeup Strength: Fragrance sales grew 6% to $628M and makeup grew 5% to $1.072B in Q3, outpacing overall growth. These categories are benefiting from premiumization trends and successful product launches, diversifying revenue beyond skin care.
- Positive Free Cash Flow: TTM free cash flow stands at $1.285B, providing financial flexibility for debt reduction, dividends, and strategic investments. This supports the balance sheet despite high leverage.
Bearish
- Persistent Downtrend and Underperformance: The stock is down 5.17% over the past year while the S&P 500 gained 21.46%, underperforming by 26.6 percentage points. The 6-month change of -14.05% and YTD change of -19.92% confirm sustained selling pressure.
- Negative Trailing EPS and Weak Profitability: Trailing EPS is -$0.04, and the net margin is -7.93%, reflecting ongoing losses. Operating margin compressed to 9.64% in Q3 from 13.85% in Q2, indicating cost pressures and restructuring expenses.
- High Leverage and Debt Burden: Debt-to-equity ratio is 2.44, indicating significant leverage. Interest expense of $82M in Q3 weighs on profitability, and the high EV/EBITDA of 184.5x suggests the market is pricing in a dramatic recovery that may not materialize.
- Skin Care Growth Lags: Skin care, the largest segment at $1.856B, grew only 2% in Q3, reflecting slow recovery in Asia. This segment is critical for overall growth, and its sluggishness limits the pace of the turnaround.
EL Technical Analysis
The stock is in a clear downtrend over the past year, with a 1-year price change of -5.17%, underperforming the S&P 500's +21.46% gain. As of August 6, 2026, the current price of $85.49 sits at 42.5% of its 52-week range (low $66.22, high $121.64), indicating the stock is closer to its lows than highs, reflecting persistent selling pressure. The 6-month change of -14.05% and YTD change of -19.92% confirm a sustained bearish trend, with the stock trading well below its 52-week high.
Beta
1.25
1.25x market volatility
Max Drawdown
-43.8%
Largest decline past year
52-Week Range
$66-$122
Price range past year
Annual Return
-3.9%
Cumulative gain past year
| Period | EL Return | S&P 500 |
|---|---|---|
| 1m | +5.5% | +2.4% |
| 3m | +2.7% | +4.7% |
| 6m | -17.3% | +11.7% |
| 1y | -3.9% | +21.3% |
| ytd | -18.3% | +13.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
EL Fundamental Analysis
Revenue has shown a modest recovery, with the most recent quarter (Q3 FY2026, ended March 31, 2026) reporting $3.712 billion, up 4.56% year-over-year from $3.55 billion in the prior-year quarter. This marks a return to growth after a period of stagnation, as the prior four quarters saw revenue declines or flat growth, including a -0.4% decline in Q2 FY2026. The growth is driven by strength in fragrance (+6% to $628 million) and makeup (+5% to $1.072 billion), while skin care, the largest segment at $1.856 billion, grew only 2%, reflecting slower recovery in Asia. The company's gross margin remains high at 71.04% in the latest quarter, but operating margin has compressed to 9.64% from 13.85% in Q2 FY2026, indicating ongoing cost pressures and investments in restructuring.
Quarterly Revenue
$3.7B
2026-03
Revenue YoY Growth
+4.6%
YoY Comparison
Gross Margin
71.0%
Latest Quarter
Free Cash Flow
$1.3B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is EL Overvalued?
Given the negative trailing EPS of -$0.04, the PE ratio is not meaningful, so I selected the PS ratio as the primary valuation metric. The current PS ratio is 2.04x, based on a market cap of $29.1 billion and trailing twelve-month revenue of approximately $14.3 billion. The forward PE of 26.78x implies the market expects a significant earnings recovery, as analysts project EPS of $4.90 for the next fiscal year, which would represent a dramatic turnaround from the current loss-making position. This gap between trailing and forward earnings suggests the market is pricing in a strong rebound in profitability, which is a key risk if the recovery disappoints.
PE
-25.7x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 28x~169x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
184.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks are substantial. The company carries a debt-to-equity ratio of 2.44, and interest expense of $82M in Q3 FY2026 consumes a significant portion of operating income. Trailing EPS is -$0.04, and the net margin is -7.93%, indicating ongoing losses. While free cash flow is positive at $1.285B TTM, the high leverage limits financial flexibility. Operating margin compression from 13.85% in Q2 to 9.64% in Q3 suggests cost pressures and restructuring costs that could persist. The negative payout ratio (-0.545) indicates dividends are not fully covered by earnings, though the yield is modest at 2.12%.
FAQ
The key risks are: (1) Financial risk: high debt-to-equity ratio of 2.44 and negative trailing EPS, which could lead to dividend cuts or financial distress if the recovery stalls. (2) Market risk: the stock is highly volatile (beta 1.246) and has underperformed the S&P 500 by 26.6 percentage points over the past year, indicating persistent selling pressure. (3) Competitive risk: intense competition from L'Oréal and Coty, especially in the prestige beauty segment, could limit market share gains. (4) Macro risk: weakness in China and travel retail, which are key growth drivers, could persist. The most severe risk is a failure to achieve the expected margin recovery, which could lead to a de-rating and a fall to the 52-week low of $66.22.
The 12-month forecast is uncertain, with a wide range of analyst targets from $70 to $125. The base case, with a 50% probability, sees the stock trading around the average target of $95.85, assuming revenue growth of 4-5% and operating margins stabilizing at 10-11%. The bull case, with a 25% probability, targets $105-$125 if the turnaround exceeds expectations, with margins expanding to 12%+ and Asia recovering strongly. The bear case, also with a 25% probability, targets $66-$75 if the recovery stalls, with margins below 9% and continued weakness in Asia. The most likely scenario is the base case, but the high uncertainty is reflected in the wide target range.
EL stock is trading at a forward PE of 26.78x, which is a premium to the broader market and to its own historical average, indicating the market is pricing in a significant earnings recovery. The PS ratio of 2.04x is reasonable for a premium brand portfolio, but the negative trailing EPS makes the PE ratio not meaningful. Compared to peers like L'Oréal, which trades at a forward PE of around 30x, EL's forward PE is slightly lower, suggesting it is not egregiously overvalued. However, the high EV/EBITDA of 184.5x reflects the market's expectation of a dramatic EBITDA recovery. The valuation implies the market expects EPS to reach $4.90 next year, which is a high bar. If the recovery is slower than expected, the stock could be considered overvalued.
EL is a good buy for investors with a high risk tolerance and a long-term horizon, given the consensus 'Buy' rating and average target price of $95.85, which implies about 12% upside. However, the stock is in a downtrend, down 19.92% YTD, and the negative trailing EPS of -$0.04 indicates the company is still in a turnaround phase. The forward PE of 26.78x suggests the market expects a strong earnings recovery, which is a risk if the recovery disappoints. The biggest downside risk is a fall to the 52-week low of $66.22, a -22.5% loss. For investors who believe in the brand strength and the independent turnaround strategy, the stock offers a compelling risk/reward, but it is not suitable for conservative investors.
EL is more suitable for long-term investment, given its turnaround nature and the need for time to execute the restructuring and margin recovery. The stock's beta of 1.246 and negative trailing EPS make it too volatile and risky for short-term trading. The dividend yield of 2.12% provides some income, but the payout ratio is negative, indicating the dividend is not fully covered by earnings. For long-term investors, a minimum holding period of 3-5 years is recommended to allow the company to recover and benefit from the prestige beauty market's growth. Short-term traders may find opportunities in the volatility, but the downtrend suggests caution.